A combination of clinical study and Network Pharmacology approach to explore the efficacy and mechanism of Buxue Yimu Pills on gynecological anemia

Yanfang Wang  
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital

Yan Deng  
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital

Ruilin Ma  
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital

Dong Liu  
West China Second Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children

Bin Luo  
West China Second Hospital, Key laboratory of Birth Defects and Related Diseases of Women and Children

Xue Wang  
Hangzhou Women's Hospital

Miao Deng  
Hangzhou Women's Hospital

Aijun Sun  
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital of Skin Diseases and Institute of Dermatology

Research

Keywords: Traditional Chinese medicine, Buxue Yimu Pills, gynecological anemia, network pharmacology, multi-target mechanism

DOI: https://doi.org/10.21203/rs.3.rs-38583/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background

Iron supplement is the first-line treatment for gynecological anemia (GA). However, its performance is limited by common gastrointestinal reactions and some inadequate responses. Traditional Chinese medicine (TCM) has a long history in the treatment of gynecological conditions but has been restricted by limited high-quality research, unknown bioactive ingredients, and mechanisms.

Objectives

These studies aim to compare the clinical efficacy of Buxue Yimu Pills (BYP), ferrous sulfate, and the addition of BYP to ferrous sulfate on GA through oral administration, and to investigate the mechanisms of BYP using network pharmacology approach.

Design:

Prospective, open-label, comparative, randomized, multicenter clinical trial.

Setting:

Gynecology departments in three public hospitals.

Patients:

170 patients with hemoglobin of 70–110 g/L were recruited and randomized into three groups: BYP group, oral iron group, and combined BYP & oral iron group. After a four-week treatment, the complete blood count (CBC) along with the markers for iron metabolism were determined for 138 patients. Furthermore, network pharmacology was performed to identify the active ingredients and potential mechanisms of BYP.

Results

While iron-treated groups showed elevated hemoglobin in accompany with significant changes in iron metabolism biomarkers, the BYP group exhibited hemoglobin improvement without apparent changes in iron metabolism markers. The network pharmacology identified 27 bioactive compounds and 145 targets of BYP on GA. A number of biological processes and pathways were identified, including regulation of inflammation, regulation of steroid hormone, angiogenesis and hemostasis, response to decreased oxygen levels, effects on myeloma cell, and response to metal ions.

Conclusions

BYP contributes to the practical improvement of gynecological anemia potentially through multi-target mechanisms independent from increasing hemopoietic raw material-iron.

Background

Anemia, one of the major public health issues worldwide, affects about one-quarter of the world's population, especially among preschool children and young women. There are many common gynecologic diseases associated with anemia, such as uterine fibroids, adenomyosis, endometrial polyps, ovulation disorders, ectopic pregnancy, and abortion, affecting especially young women. Besides, cancer-related anemia and therapy-induced anemia are common in patients with gynecological malignancies. Oral or intravenous iron supplements is the major therapeutic approach, while its common gastrointestinal side effects, including nausea, constipation, and diarrhea, can lower patient compliance. Over 40% of reproductive age women were reported to fail to adhere to medication. Moreover, patients with gynecological anemia (GA) have been observed to be associated with inflammatory states, causing limited iron absorption and utilization. Therefore, the exploration of alternative treatment options is encouraged. Traditional Chinese medicine (TCM) has been utilized to treat gynecological diseases and anemia for a long time, showing high safety, tolerability, and compliance even among the patients with malignancy, chronic kidney disease as well as the elderly. Due to the lack of high-quality randomized controlled trial (RCT) evidence and intensive study, the efficacy and therapeutic mechanisms of TCMS have yet to be well understood or appreciated.

Buxue Yimu Pills (BYP), a TCM with primary efficacy of Qi-reinforcing and nourishing blood, consists of Angelicae Sinensis Radix (Danggui), Hedysarum Multijugum Maxim (Huangqi), Colla Corii Asini (Ejiao), Leonuri Herba (Yimucao), and Citrus Reticulata (Chenpi) according to Pharmacopoeia of the People's Republic of China. Previous studies have shown that Yimucao promoted uterine contractions, thus reducing vaginal...
bleeding; Ejiao, Danggui, Huangqi, and Chenpi could benefit Qi, activate blood circulation and promote hematopoiesis; Huangqi and Danggui exerted anti-inflammatory effects. Therefore, we hypothesized that BYP could treat GA through a variety of mechanisms.

To comprehensively assess its clinical effect and herbal pharmacological mechanisms, we performed a randomized clinical trial at three centers, followed by a network pharmacology research.

**Materials And Methods**

**Clinical study**

**Experimental design and setting.**

To compare the effects of Buxue Yimu Pills (BYP), ferrous sulfate, and a combination of both treatments on GA, a prospective, randomized controlled trial was conducted between 2017 and 2019 at Gynecology departments of three public hospitals, including Peking Union Medical College Hospital (PUMCH), West China Hospital of Sichuan University, and Hangzhou Maternity and Child Health Care Hospital. This study was approved by the Ethics Committee of PUMCH (No. ZS-1254) at January 2017, and registered at the United States National Institutes of Health (registration number NCT03232554, www.clinicaltrials.gov).

**Patients**

Adult females aged 18–50 years with hemoglobin of 70-110 g/L associated with gynecological disorders were enrolled following the informed consent. Exclusion criteria were: (1) patients with uncontrolled gastrointestinal inflammation or bleeding or urological bleeding; (2) patients presented with other diseases leading to iron deficiency; (3) pregnant women; (4) patients complicated with mental abnormalities or other severe diseases; (5) patients with a history of malignancy, chemotherapy or radiotherapy; (6) patients treated with iron supplements, blood transfusion or participating in any other clinical trial within the past month. Eligible participants were randomized into three groups: BYP group received Buxue Yimu Pills (24 g/day); oral iron group received ferrous sulfate tablets (0.9 g/day), and BYP & oral iron group received both drugs above simultaneously. All drugs were provided by ZhuZhou QianJin Pharmaceutical Co., Ltd. The total treatment periods were four weeks.

**Assessments**

Assessments were scheduled pre-and post-treatment. A basic physical examination including vital signs, weight, height, body mass index (BMI), blood pressure was performed. Venous blood samples were collected to detect complete blood count, including hemoglobin (Hb), mean cellular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red blood cells (RBC), hematocrit (HCT), reticulocyte (RET) count. Iron indexes of serum iron (SI), serum ferritin (SF), and total iron-binding capacity (TIBC) were analyzed. Moreover, the safety assessment, including liver function, renal function, and a blood coagulation index, were also evaluated (data not shown).

**Statistical analysis**

Statistical analysis was carried out using SPSS version 20.0 (IBM). Data from normally distributed parameters are presented as means plus or minus standard deviation (SD); paired t-tests were used to compare the intragroup difference pre- and post-treatment, and one-way analysis of variance (ANOVA) was applied for intergroup comparisons. Variables not normally distributed are expressed as median plus 25-75 interquartile range (IQR); intragroup and intergroup comparisons were evaluated with Wilcoxon matched-pairs signed-rank tests and Kruskal-Wallis tests. A p-value of less than 0.05 (p < 0.05) was considered significant in all statistical analyses.

**Network pharmacology analysis**

**Bioactive compounds and compound targets of Buxue Yimu Pills**

Composite compounds were searched manually with the major ingredients of BYP “Angelicae Sinensis Radix”, “Hedysarum Multijugum Maxim”, “Colla Corii Asini”, “Leonuri Herba” and “Citrus Reticulata”, in Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TcmSP, http://lsp.nwu.edu.cn/tcmsp.php) and Database of Traditional Chinese Medicine and chemical composition from Shanghai Institute of Organic Chemistry (http://www.organchem.csdb.cn/scdb/main/tcm_introduce.asp). Next, a combination of oral bioavailability ≥30% along with drug-likeness ≥0.18 was applied to explore the bioactive compounds. Potential treatment targets of those bioactive compounds were subsequently obtained from TcmSP; and converted to target genes with official symbols using Uniprot Knowledgebase (http://www.uniprot.org/).

**Target genes of GA**

GA-associated targets were retrieved from the Online Mendelian Inheritance in Man (OMIM) database (https://www.omim.org/) and GeneCard Database (https://www.genecards.org/), using “gynecological anemia” as the keyword. Data were extracted and summarized without duplication.

**Network construction**
Potential therapeutic targets are the intersections between the compound targets of BYP and GA-associated targets, which were generated with the VennDiagram R package. After importing the main ingredients, bioactive compounds, and potential therapeutic targets, the compound-target-disease network was built and visualized by Cytoscape software (version 3.6.1, http://cytoscape.org/).

Functional analysis

Based on the obtained potential therapeutic targets, enrichment analysis was performed using the online tool Metascape (https://metascape.org) 15, including Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis.

A protein-protein interaction (PPI) network was constructed via STRING (Version 11.0, https://string-db.org/) with a minimum required interaction score of 0.400. We subsequently used the Molecular Complex Detection tool (MCODE) plugin to identify significant clusters in this PPI network.

Results

Baseline characteristics

Out of 170 enrolled patients with GA, 138 patients (81.2%) completed the four-week treatment and were included in the data analysis: BYP group (n=58), oral iron group (n=37), and the combination group (n=43). The baseline characteristics of all three groups showed no statistical difference (Table 1).

Laboratory parameters

Table 2 shows the values of laboratory parameters before and after treatment. After four weeks of treatment, patients in three groups exhibited a significant increase in Hb, RBC, and HCT (p<0.01), but no significant differences in RET. The changes of Hb (g/L) are listed in the following: BYP group (16.44±14.12), oral iron group (30.84±15.46), and the combination group (37.82±16.9). Pairwise comparison show there are statistically significant differences between BYP group and oral iron group (p<0.01) or BYP group and the combination group (p<0.01), while differences between the two iron-containing groups were not remarkable (p=0.062) (Figure 1).

According to the iron indexes, it is expected that there were significant increases in SI and SF accompanied by a substantial decrease in TIBC in the oral iron group (p<0.01), but no differences were detected in BYP group (p>0.05). However, unexpectedly, the combination group, whose Hb was improved most significantly after treatment, showed noticeable increases in SI and SF but no apparent change in TIBC.

Compound-target-disease network

Thirty-two molecules, the bioactive compounds, with oral bioavailability ≥ 30% and drug-likeness ≥ 0.18 were identified through network pharmacology analysis (Table 3), which belongs to the ingredients of Huangqi (20), Yimucao (8), Chenpi (5), and Danggui (2), respectively.

Kaempferol (MOL000422, a unique given ID from TcmSP), quercetin (MOL000098), and isorhamnetin (MOL000354) are the three components common in Huangqi and Yimucao. ZINC14758732 (MOL000438), Jaranol (MOL000239), isoflavonone (MOL000398), isoumacronulatol-7,2’-di-O-glucosiole (MOL000439), and 5’-hydroxyiso-muronulatol-2’,5’-di-O-glucoside (MOL000374) in Huangqi were not included in this network. 1657 potential treatment targets of BYP with social symbols and 270 target genes of GA were identified, among which a number of 145 genes intersected (Figure 2(a)). The compound-target-disease network was constructed with 818 nodes and 1436 connecting edges and shown in Figure 2(b). After analyzing the network with the NetworkAnalyzer plugin in Cytoscape, quercetin (MOL000098, mol17), which is shared by Huangqi and Yimucao, was identified as the most important compound with the overwhelmingly highest degree of 107. Evidence from previous studies has shown that quercetin can improve inflammation and chemotherapy-related anemia through reducing oxidative stress, ameliorating the iron status and protecting red blood cells16-18.

Functional analysis

Figure 3 shows the results of functional enrichment analysis: KEGG pathway, Gene Ontology Biological Process (GOBP), Gene Ontology Cellular Component (GOCC), and Gene Ontology Molecular Function (GOMF), which were mostly associated with cancer, inflammation, steroid hormone regulation, oxidative stress, metabolic syndrome, nervous system diseases, and infectious diseases. Many of these terms are too general for annotation, so we took a deeper insight into their child function clusters and further summarized the biological processes into several underlying functional modules: regulation of inflammation, regulation of steroid hormone, angiogenesis and hemostasis, response to decreased oxygen levels, effects on myeloma cell and response to metal ion (Supplementary Table 1). The biological processes with the highest enrichment score in each module were selected to build a compound-target-underlying biological process network (Figure 4), with 139 nodes, 483 edges.

Protein-protein interaction (PPI) network of intersecting targets was constructed with STRING, including 145 nodes and 3196 edges (Figure 5(a)). According to the selection criteria of MCODE scores ≥ 5, degree cutoff = 2, node score cutoff = 0.2, K-core = 2, and max depth = 100, a total of 6 significant clusters were identified (Figure 5(b), Supplementary Table 2).

Discussion
Consistent with previous studies, after four-week treatment, patients taking ferrous sulfate or ferrous sulfate &BYP showed an elevation of Hb in accompany with significant changes in iron metabolism markers, typically with elevated SI, Fer, and decreased TIBC (oral iron group). One unexpected finding was that we did not find a significant decline of TIBC in the combination group, even though it did show a most significant increase in Hb. BYP group also exhibited hemoglobin improvement without obvious changes in iron metabolism markers. This result may be explained by the fact that patients with GA are commonly found to have several closely related features: abnormal uterine bleeding (AUB), iron deficiency anemia (IDA), chronic inflammatory state. On the one hand, an inflammatory state can upregulate the level of hepcidin, a liver-specific peptide, increasing the degradation of ferroportin (FPN) at enterocytes, hepatocytes, and macrophages, leading to iron overload in nonhematopoietic cells but the iron deficiency in erythroid precursors. In addition, chronic inflammation can cause unbalanced blood production of hematopoietic stem cells (HSCs), impaired HSC self-renewal as well as impaired erythroid production. The previous study has found a negative correlation between Hb concentration and inflammatory markers, especially interleukin 6 (IL-6). As mentioned before, Buxue Yimu Pills can reinforce qi and nourish the blood, whose main components have previously been observed to have different efficacies of promoting hematopoiesis and anti-inflammatory effects. After treatment, with decreased inflammation and increased hematopoiesis, iron in nonhematopoietic cells can be transported to erythroid precursors more efficiently; subsequently, levels of circulating iron decrease. As a consequence, we did observe a slight upward trend of TIBC in the BYP group and an offsetting decline of TIBC in the combination group, while Hb in both groups elevated.

We also used network pharmacology technology to investigate the mechanisms of Buxue Yimu Pills further. From the compound-target-disease network, 27 bioactive compounds in Buxue Yimu Pills were identified, among which quercetin, a common component of *Huangqi* and *Yimucao*, may play a critical role. One hundred forty-five potential therapeutic targets of these compounds were confirmed. Biological process and pathway enrichment analysis demonstrated that multiple mechanisms including regulation of inflammation, regulation of steroid hormone, angiogenesis and hemostasis, response to decreased oxygen levels, effects on myeloma cell as well as response to metal ions, may contribute to improving GA. Previous studies have demonstrated that reduction of inflammation and oxidative stress can alleviate the absorption and utilization of iron, increase the production of erythropoietin (EPO) and improve hematopoietic function. Metal ion transmembrane transport contributed to iron uptake and maintenance of iron homeostasis. In addition, ovulation disorders and coagulation dysfunction have been the main nonstructural etiologies of AUB. Therefore, the regulation of steroid hormone and hemostasis can have significant implications for this condition.

Since Buxue Yimu Pills may improve anemia through multiple targets, it could have potential applications in diseases needing to deal with oxidative stress damage, such as thalassemia and inflammatory anemia. But on the other hand, one crucial point that needs to be raised is that reduction of oxidative stress might reduce the therapeutic efficacy of anti-neoplastic drugs acting through mechanisms of reactive oxygen species (ROS)-induced injury, which was also indicated in KEGG enrichment (hsa01524, platinum drug resistance). Therefore, Buxue Yimu Pills may not be recommended to patients undergoing cancer treatment.

**Conclusion**

A combination of clinical study and network pharmacology approaches not only demonstrates that Buxue Yimu Pills contributes to the effective improvement of GA through multiple mechanisms but also provides us more comprehensive insights into integrated multidimensional relationships between drugs and diseases. Finally, some limitations need to be acknowledged. The sample size and the follow-up duration may have been insufficient to reveal apparent differences between cohorts, and inflammatory indicators were not monitored. Accordingly, based on the results of our study, continued efforts are needed to further verification through larger-scale, more prolonged follow-up cohort research with targeted designs, as well as molecular mechanism studies.

**Abbreviations**

ANOVA: one-way analysis of variance; AUB: abnormal uterine bleeding; BYP: Buxue Yimu Pills; CBC: complete blood count; EPO: erythropoietin; FPN: ferroportin; GA: gynecological anemia; GO: Gene Ontology; GOBP: Gene Ontology biological process; GOCC: Gene Ontology Cellular Component; GOMF: Gene Ontology molecular function; Hb: hemoglobin; HCT: hematocrit; HSC: hematopoietic stem cell; IBM: International Business Machines Corporation; IDA: iron deficiency anemia; IL: interleukin; IQR: interquartile range; KEGG: Kyoto Encyclopedia of Genes and Genomes; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; MCODE: Molecular Complex Detection tool; MCV: mean cellular volume; OMIM: Online Mendelian Inheritance in Man; RBC: red blood cells; RET: reticulocyte; ROS: reactive oxygen species; SD: standard deviation; SF: serum ferritin; SI: Iron indexes of serum iron; TCM: Traditional Chinese medicine; TcmSP: Traditional Chinese Medicine System Pharmacology Database and Analysis Platform; TIBC: total iron-binding capacity

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the Ethics Committee of Peking Union Medical College Hospital (No. ZS-1254) at January 2017, and registered at the United States National Institutes of Health (registration number NCT03232554, [www.clinicaltrials.gov](http://www.clinicaltrials.gov)). A written informed consent was signed by all
participants.

Consent to publish

Not applicable.

Availability of data and materials

All relevant data and materials are within the paper and its additional files.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was financially supported by ZhuZhou QianJin Pharmaceutical Co., Ltd.

Authors' Contributions

WYF implemented the research plan and was responsible for data curation, data mining/formal analysis, conceptualization and writing of the manuscript. DY, MRL, LD, WX, DM participated in the enrollment of the patients and data collection. SAJ provided a critical contribution to the organization and cooperation of this multi-center task.

Acknowledgements

The authors thank ZhuZhou QianJin Pharmaceutical Co., Ltd. for funding and research support for this study. The authors declare that there are no conflicts of interest.

Author details

1 Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing100730, China.

2 West China Second Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Sichuan University, Chengdu 610041, Sichuan, China.

3 Hangzhou Women's Hospital (Hangzhou Maternity and Child Health Care Hospital), Hangzhou 310008, China.

* Correspondence: saj_pumch@sina.com.

References

1. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr. 2009;12(4):444-54.

2. Hisa K, Haruna M, Hikita N, Sasagawa E, Yonezawa K, Suto M, et al. Prevalence of and factors related to anemia among Japanese adult women: Secondary data analysis using health check-up database. Sci Rep. 2019;9(1):17048.

3. NJ K, R J, M N, SK W, N J, R L, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123(5):615-24.

4. Maccio A, Madeddu C, Gramignano G, Mulas C, Tanca L, Cherchi MC, et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica. 2015;100(1):124-32.

5. Gunderson CC, Matulonis U, Moore KN. Management of the toxicities of common targeted therapeutics for gynecologic cancers. Gynecol Oncol. 2018;148(3):591-600.

6. Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381(25):2391-402.

7. Gereklioglu C, Asma S, Korur A, Erdogan F, Kut A. Medication adherence to oral iron therapy in patients with iron deficiency anemia. Pak J Med Sci. 2016;32(3):604-7.

8. Maybin JA, Critchley HO. Menstrual physiology: implications for endometrial pathology and beyond. Hum Reprod Update. 2015;21(6):748-61.

9. Maccio A, Madeddu C, Massa D, Mudu MC, Lusso MR, Gramignano G, et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood. 2005;106(1):362-7.

10. Hershko C, Camaschella C. How I treat unexplained refractory iron deficiency anemia. Blood. 2014;123(3):326-33.
11. Chen WD, Huang HS, Su YC, Chou SC, Ho WC, Kao MC, et al. The characteristics and prescription patterns of Chinese herbal medicine in clinical practice for the treatment of anemia. Taiwan J Obstet Gynecol. 2018;57(4):570-7.
12. Waldvogel S, Pedrazzini B, Vaucher P, Bize R, Comuz J, Tissot JD, et al. Clinical evaluation of iron treatment efficiency among non-anemic but iron-deficient female blood donors: a randomized controlled trial. Bmc Med. 2012;10.
13. Liu JY, Morisseau C, Huang H, Hammock BD. Screening of soluble epoxide hydrolase inhibitory ingredients from traditional Chinese medicines for anti-inflammatory use. J Ethnopharmacol. 2016;194:475-82.
14. Zhong LJ, Hua YL, Ji P, Yao WL, Zhang WQ, Li J, et al. Evaluation of the anti-inflammatory effects of volatile oils from processed products of Angelica sinensis radix by GC-MS-based metabolomics. J Ethnopharmacol. 2016;191:195-205.
15. Y Z, B Z, L P, M C, AH K, O T, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. 2019;10(1):1523.
16. Sen G, Mandal S, Saha Roy S, Mukhopadhyay S, Biswas T. Therapeutic use of quercetin in the control of infection and anemia associated with visceral leishmaniasis. Free Radic Biol Med. 2005;38(9):1257-64.
17. Mahoney SE, Davis JM, Murphy EA, McClellan JL, Pena MM. Dietary quercetin reduces chemotherapy-induced fatigue in mice. Integr Cancer Ther. 2014;13(5):417-24.
18. Al Balushi H, Hannemann A, Rees D, Brewin J, Gibson JS. The Effect of Antioxidants on the Properties of Red Blood Cells From Patients With Sickle Cell Anemia. Front Physiol. 2019;10:976.
19. Berbic M, Ng CH, Fraser IS. Inflammation and endometrial bleeding. Climacteric. 2014;17 Suppl 2:47-53.
20. Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832-43.
21. Pietras EM. Inflammation: a key regulator of hematopoietic stem cell fate in health and disease. Blood. 2017;130(15):1693-8.
22. Kovtonyuk LV, Fritsch K, Feng X, Manz MG, Takizawa H. Inflamm-Aging of Hematopoiesis, Hematopoietic Stem Cells, and the Bone Marrow Microenvironment. Front Immunol. 2016;7:502.
23. King KY, Goodell MA. Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat Rev Immunol. 2011;11(10):685-92.
24. Xiao H, Xiong L, Song X, Jin P, Chen L, Chen X, et al. Angelica sinensis Polysaccharides Ameliorate Stress-Induced Premature Senescence of Hematopoietic Cell via Protecting Bone Marrow Stromal Cells from Oxidative Injuries Caused by 5-Fluorouracil. Int J Mol Sci. 2017;18(11).
25. Angmo S, Tripathi N, Abbat S, Sharma S, Singh SS, Halder A, et al. Identification of Guanosine 5’-diphosphate as Potential Iron Mobilizer: Preventing the Hepcidin-Ferroportin Interaction and Modulating the Interleukin-6/Stat-3 Pathway. Sci Rep. 2017;7:40097.
26. Thompson K, Molina RM, Brain JD, Wessling-Resnick M. Belgrade rats display liver iron loading. J Nutr. 2006;136(12):3010-4.
27. Gulec S, Collins JF. Investigation of iron metabolism in mice expressing a mutant Menke’s copper transporting ATPase (Atp7a) protein with diminished activity (Brindled; Mo (Br) (y/y) ). PLoS One. 2013;8(6):e66010.
28. Marnach ML, Laughlin-Tommaso SK. Evaluation and Management of Abnormal Uterine Bleeding. Mayo Clin Proc. 2019;94(2):326-35.
29. Shankar M, Lee CA, Sabin CA, Economides DL, Kadir RA. von Willebrand disease in women with menorrhagia: a systematic review. BJOG. 2004;111(7):734-40.
30. N L, C S, B Z, H X, D M, G C, et al. Low concentration of quercetin antagonizes the cytotoxic effects of anti-neoplastic drugs in ovarian cancer. 2014;9(7):e100314.

Tables

Table 1. Comparison of patient characteristics and laboratory data at baseline.
### Table 2: The comparison of blood indices and iron metabolism markers between three groups before and after the 4-week treatment.

|                  | BYP (n=58) | Iron (n=37) | BYP & Iron (n=43) | P value |
|------------------|------------|-------------|-------------------|---------|
| Pre              |            |             |                   |         |
| 4 weeks          |            |             |                   |         |
| Hb (g/L)         | 93.56±10.05| 110±13.87*  | <0.01*            | 93.97±9.75 | 124.81±13.87* | <0.01* | 91.13±11.14 | 128.95±12.88* | <0.01* |
| MCV (fl)         | 79.28±9.07 | 78.5±8.73   | <0.01*            | 80.19±7.77 | 84.97±7.42*   | <0.01* | 77.38±9.19 | 83.37±7.16*   | <0.01* |
| MCH (pg)         | 25.17±3.59 | 24.78±3.33  | <0.01*            | 25.24±3.63 | 27.53±3.00*   | <0.01* | 24.05±4.08 | 27.01±2.64*   | <0.01* |
| MCHC (g/L)       | 307.1±47.3 | 314.32±11.48| <0.01*            | 309.14±16.25| 324.59±13.5*  | <0.01* | 308.42±19.75| 323.18±10.56* | <0.01* |
| RBC (*10^9/L)    | 3.78±0.53  | 4.46±0.42*  | <0.01*            | 3.71±0.49  | 4.57±0.60*    | <0.01* | 3.86±0.54  | 4.8±0.47*     | <0.01* |
| HCT (%)          | 29.85±2.78 | 30.49±2.58  | <0.01*            | 29.36±2.85 | 39.74±4.00*   | <0.01* |            |              |            |
| RET              | 77.9(55.5,99.4) | 70.1(35.3,97.9) | <0.01*          | 77.38±9.19 | 83.37±7.16*   | <0.01* | 81.1(57.5,109.4) | 0.091 |
| SI (umol/L)      | 15.20(7.78,33.25) | 20.00(10.35,26.50) | <0.01*        | 13.10(8.1,22.55) | 26.10(13.90,59.90) | <0.01** |            |              |            |
| Fer (ug/L)       | 9.7(4.1,22.6) | 8.0(5.0,18.5) | <0.01*            | 9.0(4.0,14.2) | 26.5(14.5,31.8) | <0.01** | 9.4(4.0,33.5) | 30.0(16.0,42.6) | 0.022** |
| TIBC (g/L)       | 361.0(57.6,415.0) | 344.5(58.9,406.5) | <0.01**        | 344.5(58.9,406.5) | 274.0(61.8,367.8) | <0.01** | 321.0(57.7,411.5) | 310.0(67.2,343.0) | 0.081 |

Note: Significant difference with Paired T test (*) or Wilcoxon test (**)

### Table 3: Main ingredients of Buxue Yimu Pills and their bioactive compounds.
| Ingredients (Chinese name) | English name | Latin name | Mol ID | Molecule Name | OB (%) | DL |
|---------------------------|-------------|------------|--------|---------------|--------|----|
| **Chenpi** | Dried Tangerine peel | Citrus | MOL004328 | naringenin | 59.29 | 0.21 |
| |  | Reticulata | MOL005100 | (Rac)-Hesperetin | 47.74 | 0.27 |
| |  |  | MOL005815 | Citromitin | 86.9 | 0.51 |
| |  |  | MOL005828 | nobiletin | 61.67 | 0.52 |
| |  |  | MOL00359 | sitosterol | 36.91 | 0.75 |
| **Danggui** | Angelica | Angelicae | MOL000358 | beta-sitosterol | 36.91 | 0.75 |
|  | Sinensis Radix |  | MOL000449 | Stigmasterol | 43.83 | 0.76 |
| **Huangqi** | Astragalus | Hedysarum | MOL000392 | formononetin | 69.67 | 0.21 |
| |  | Multijugum | MOL000422 | kaempferol | 41.88 | 0.24 |
| |  |  | MOL000417 | Calycosin | 47.75 | 0.24 |
| |  | Maxim. | MOL000438* | ZINC14758732 | 67.67 | 0.26 |
| |  |  | MOL000098 | quercetin | 46.43 | 0.28 |
| |  |  | MOL000239* | Jaranol | 50.83 | 0.29 |
| |  |  | MOL000398* | isoflavonone | 109.99 | 0.3 |
| |  |  | MOL000378 | 7-O-methylisomucronulatol | 74.69 | 0.3 |
| |  |  | MOL000354 | isorhamnetin | 49.6 | 0.31 |
| |  |  | MOL000380 | Astrapterocarpan | 64.26 | 0.42 |
| |  |  | MOL000371 | 3,9-di-O-methylisnissolin | 53.74 | 0.48 |
| |  |  | MOL000442 | 1,7-Dihydroxy-3,9-dimethoxypterocarpene | 39.05 | 0.48 |
| |  |  | MOL000439* | isomucronulatol-7,2′-di-O-glucosiole | 49.28 | 0.62 |
| |  |  | MOL000387 | Bifendate | 31.1 | 0.67 |
| |  |  | MOL000374* | 5′-hydroxyisomucronulatol-2′,5′-di-O-glucoside | 41.72 | 0.69 |
| |  |  | MOL000433 | FA | 68.96 | 0.71 |
| |  |  | MOL000296 | hederagenin | 36.91 | 0.75 |
| |  |  | MOL000211 | Mairin | 55.38 | 0.78 |
| |  |  | MOL000033 | (24S)-24-Propylcholesta-5-ene-3β-ol | 36.23 | 0.78 |
| |  |  | MOL000379 | 9,10-dimethoxypterocarpan-3-O-β-D-glucoside | 36.74 | 0.92 |
| **Yimucao** | Motherwort | Leonuri | MOL001439 | arachidonic acid | 45.57 | 0.2 |
| |  | Herba | MOL000422 | kaempferol | 41.88 | 0.24 |
| |  |  | MOL000098 | quercetin | 46.43 | 0.28 |
| |  |  | MOL000354 | isorhamnetin | 49.6 | 0.31 |
| |  |  | MOL001422 | iso-preleoheterin | 66.29 | 0.33 |
| |  |  | MOL001421 | preleoheterin | 85.97 | 0.33 |
| |  |  | MOL001418 | galeopsin | 61.02 | 0.38 |
| |  |  | MOL001420 | beta-Sitosterone | 38 | 0.76 |

Note: * indicates the component not involved in the following network.
Figure 1

Changes in hemoglobin after 4-week treatment in three groups.

Figure 2

The pharmacology network generated for BYP. (a) Intersection of drug-target and disease-target. (b) Compound-target-disease network with 176 nodes, 409 edges. Red oblong nodes represent target genes; green square nodes represent bioactive compounds; polygon nodes of different colors represent main ingredients of Buxue Yimu Pills. The node size is proportional to degree. Notes: YMC, Yimucao; HQ, Huangqi; CP, Chenpi; DG, Danggui.
Figure 3

Results of functional enrichment analysis: KEGG pathway, GOBP, GOCC and GOMF.
Figure 4

Compound-target-underlying biological process network with 139 nodes, 483 edges. Red oblong nodes represent target genes; green square nodes represent bioactive compounds; Blue polygon nodes represent main underlying biological processes. Edges between biological processes and targets are shown in red; edges between bioactive compounds and targets are shown in grey.

Figure 5

PPI network (145 nodes, 3196 edges) and 6 clusters were identified using MCODE. Seed target proteins are represented in yellow.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1.pdf
- Additionalfile2.pdf
- Additionalfile3.pdf